ESMO 2025

Toward a new standard - T-DXd in early breast cancer

Reassuring data on pregnancy for young EBC patients

Refining the standard treatments for early breast…

Confirmative OS data on CDK4/6 inibitors for pts with…

Durvalumab improves OS in TNBC

OS-benefit with abemaciclib

CDK4/6 inhibitors – confirmed effect

First time OS - confirming clinical practice

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

Financial toxicity

New insights into PROTAC SERD vepdegestrant

T-DXd in high-risk patients in the postneoadjuvant…

POSITIVE trial - update

Exciting news for young patients who want to get…

Optimizing G-CSF administration helps reducing side…

Ki67 after preoperative chemotherapy - a new strong…

Great update for young women

Optimal timepoint of G-CSF administration after…

T-DXd neoadjuvant improves pCR

A first step into a great story

Individual consultation remains important

T-DXd right from the start – in a neoadjuvant situation…

monarchE OS

Studio POSITIVE - aggiornamento

Un primer paso hacia una gran historia

Momento óptimo para la administración de G-CSF después…

Ki67 po przedoperacyjnej chemioterapii - nowy istotny…

monarchE OS

Prima valutazione della OS: conferma della pratica…

Practice changing data for firstline TNBC

Future perspectives for firstline therapy

ADCs in mBC - the story is not finished

Another good option for patients with mTNBC

Meeting the unmet need in advanced TNBC not eligible…

Survival data from SONIA

Breakthroughs for high-risk patients

Transforming TNBC

Early positioning of third-generation ADCs in treatment

Gedatolisib in patients with PI3K wild type HR+ mBC

Stronger together

Should this drug be available outside of China?

Changing the paradigm of treatment in 1L of TNBC

Reforming destiny

ADCs are coming for first line TNBC

Which ADC in 1L for metastatic TNBC

TROP2 number 3

TROP2 ADC, the second

ADC, the first

Gedatolisib chez les patients atteints d'un cancer du…

Gli ADC si fanno strada nella prima linea del TNBC

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Positionnement plus précoce des ADCs de troisième…

La combinazione conta

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Più forti insieme

Cambiando el paradigma del tratamiento en la primera…

Immunotherapy and biomarkers in resectable NSCLC:…

Evolving immunotherapy approaches in locally advanced…

Neoadjuvant chemo/immuno - the bridge to make…

A bridge to surgery

New targeted therapies in HER2-mutated NSCLC

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

NorthStar: Osimertinib ± local therapy in EGFR-mutant…

Ivonescimab in NSCLC - a new SOC?

New kid on the block for EGFRm

EGFR exon 20 - What does the future hold?

New chances for locally advanced NSCLC

The added value of radiotherapy in EGFR mutated NSCLC

Save and effective - Ivonescimab in HARMONi-6

NorthStar - new navigation principle

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

HER2 altered - small population, many options

Sac-TMT - a potential new option for EGFRm NSCLC…

Alectinib remains a potential SOC

New treatment options for HER2-mutation positive NSCLC

New options after EGFR-TKI failure

The return of antiangiogenic strategy in squamous NSCLC

Update for pts with BRAF mutation

New prospect for squamous tumors

Two frontline HER2-options - is this the future?

ALK - longterm

Sac-TMT now also available for NSCLC

Local therapy in addition to osimertinib 1st line in…

Is chemo-IO an option if you want a rapid response in…

Local ablative therapy in EGFR-mutated NSCLC

Is this the end for pembrolizumab?

Eradication of all disease - is this the true north?

Treat your BRAF-patients in 1L

Two is better than one

Nuevas perspectivas para los tumores escamosos

Due è meglio di uno

Sac - TMT - une nouvelle option potentielle pour le…

Le retour de la stratégie antiangiogénique dans le…

È la fine per Pembrolizumab?

ADCS anti-TROP-2 - nouvelles données sur le EGFRm NSCLC

De toegevoegde waarde van radiotherapie bij…

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

Long-term outcomes with tepotinib in METex14 skipping…

T-cell engager in 1st line SCLC

DLL3 targeting drugs moving to frontline therapy

Bending the gravity of SCLC

Will tarlatamab improve 1st line treatment for…

Tarlatamab combination in 1st line SCLC

Amélioration spectaculaire de la survie sans…

Zal tarlatamab de eerstelijnsbehandeling van…

A new class of drugs in Mesothelioma treatment

A step in the right direction

Adding to the adjuvant RCC story - how do we move…

Therapy-relevant aspects for first-line treatment of…

Adjuvans in high risk RCC after surgery

More evidence in second-line treatment for metastatic…

Kidney cancer advances from ESMO

Further intensification of therapy with potential…

The dawn of molecular imaging in renal cell carcinoma

LenCabo - early activity, but we need more data

Relevance of CPI neoadjuvant and adjuvant

NMIBC: Making the right choice for high risk patients!

UTUC: Impressive PFS und OS Benefit with Disitamab…

MIBC: Is ctDNA monitoring ready for daily practice?

Therapy intensification in patients ineligible for…

When precision matters, the case of ctDNA in MIBC

Neoadjuvant combination of local and systemic therapy…

Neoadjuvant HER2-targeted therapy for kidney-sparing…

Dose modifications, new combinations, new substances in…

Adding checkpoint inhibitor in high risk NMIBC shows…

A well-tolerated and effective new neoadjuvant concept…

Setting the bar even higher in MIBC

Better QoL for patients with metastatic bladder cancer

A highly selective FGFR3 inhibitor for first-line…

De-escalation promotes a better QoL while maintaining…

The ADC story continues

New benchmark for MIBC and platinum-unsuitable patients

Too early for primetime

Is ICI to BCG suitable for NMIBC?

ADC Enfortumab vedotin + Pembrolizumab in MIBC

New options for neoadjuvant therapy in MIBC

A newcomer in advanced urothelial cancer

Perioperative and adjuvant standards for MIBC

Bladder cancer highlights from ESMO 2025

Cuando la precisión importa: el caso de ctDNA en MIBC

Un recién llegado en el cáncer urotelial avanzado

Elevando aún más el estándar en MIBC

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

A Game-Changer for Early Relapse?

Changed chemo-regimen leads to less toxicity in mHSPC

OS-benefit in BCR

Final OS results for EMBARK

Impressive OS-data from EMBARK

Example for biomarker guided precision medicine in…

Docetaxel vs. Lutetium in chemosensitive mCRPC

Triplet regimen with reduced chemotherapy – fewer side…

PSMAddition - Is it time for more?

New docetaxel regimen in combination with darolutamide…

The role of lutetium in mHSPC – is its use clinically…

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Exempel på biomarkörstyrd precisionsmedicin vid…

Social Listening